Table 4. Tumor response per RECIST v1.1.

Best overall response	n (%)
	50 mg QD (n=3)	100 mg QD (n=3)	200 mg QD (n=3)	300 mg QD (n=3)	400 mg QD (n=3)	500 mg QD (n=3)	600 mg QD (n=4)	300 mg BID (n=6)	All patients (n=28)
RECIST, response evaluation criteria in solid tumors; DCR, disease control rate. *, Patient no identifiable lesions on imaging but more than 6 years on Hemay022 without progression.
Complete response	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	0 (0)	1 (3.6)
Partial response	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	2 (33.3)	3 (10.7)
Stable disease	0 (0)	2 (66.7)	2 (66.7)	1 (33.3)	0 (0)	0 (0)	2 (50.0)	2 (33.3)	9 (32.1)
Not available	/	/	/	/	/	1 (33.3)*	/	/	1 (3.6)
DCR [% (95% CI)]	0	66.7 (13.3−100)	66.7 (13.3−100)	66.7 (13.3−100)	0	33.3 (0−86.7)	50.0 (1.0−99.0)	66.7 (28.9−100)	46.4 (28.0−64.9)